<p>Shield Therapeutics plc (LON:STX - 獲取免費報告) 的股價在週二的交易中跌破了其 50 日移動平均線。該股的 50 日移動平均線為 GBX 9.39，最低交易價為 GBX 7.50。Shield Therapeutics 的股票最後交易價為 GBX 7.75，成交量為 5,318,340 股。</p>
<p>獲取 <strong>Shield Therapeutics</strong> 的提醒：</p>
<h2>Shield Therapeutics 股價上漲 8.7%</h2>
<p>該公司的負債權益比為-182.06，速動比率為 2.16，流動比率為 0.83。該公司的市值為 9174 萬英鎊，市盈率為-4.30，貝塔係數為 1.91。該股的 50 日簡單移動平均線為 GBX 9.39，200 日簡單移動平均線為 GBX 9.04。</p>
<h2>Shield Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Shield 是一家商業階段的專業製藥公司，提供 Accrufer®/Feraccru®（鐵麥芽糖），這是一種創新且差異化的藥品，旨在滿足鐵缺乏症患者（無論是否伴有貧血）的重大未滿足需求。該公司已在美國推出 Accrufer®，並與 Viatris Inc（Viatris）簽署了獨家多年的商業協議。在美國以外，該公司已將權利授權給四家專業製藥公司。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Shield Therapeutics</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Shield Therapeutics 嗎？</h2>
<p>在考慮投資 Shield Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Shield Therapeutics 並不在名單上。</p>
<p>雖然 Shield Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SEELQ

NBSE.ESC

PSTV

SEEL

<p>Shield Therapeutics（倫敦證券交易所代碼：STX）股價跌破其 50 日移動平均線 9.39 便士，最低交易價為 7.50 便士，最終收於 7.75 便士。該股票的交易量為 5,318,340 股。公司市值為 9174 萬英鎊，市盈率為-4.30，負債權益比為-182.06。儘管分析師給予 “買入” 評級，但 Shield Therapeutics 並不是頂級分析師推薦的股票之一</p>

<p>Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 9.39 and traded as low as GBX 7.50. Shield Therapeutics shares last traded at GBX 7.75, with a volume of 5,318,340 shares changing hands.</p>
<div class="lb-trans"><p>Shield Therapeutics plc (LON:STX - 獲取免費報告) 的股價在週二的交易中跌破了其 50 日移動平均線。該股的 50 日移動平均線為 GBX 9.39，最低交易價為 GBX 7.50。Shield Therapeutics 的股票最後交易價為 GBX 7.75，成交量為 5,318,340 股。</p>
</div><p>Get <strong>Shield Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Shield Therapeutics</strong> 的提醒：</p>
</div><h2>Shield Therapeutics Trading Up 8.7%</h2>
<div class="lb-trans"><h2>Shield Therapeutics 股價上漲 8.7%</h2>
</div><p>The company has a debt-to-equity ratio of -182.06, a quick ratio of 2.16 and a current ratio of 0.83. The firm has a market capitalization of £91.74 million, a PE ratio of -4.30 and a beta of 1.91. The stock's 50-day simple moving average is GBX 9.39 and its 200-day simple moving average is GBX 9.04.</p>
<div class="lb-trans"><p>該公司的負債權益比為-182.06，速動比率為 2.16，流動比率為 0.83。該公司的市值為 9174 萬英鎊，市盈率為-4.30，貝塔係數為 1.91。該股的 50 日簡單移動平均線為 GBX 9.39，200 日簡單移動平均線為 GBX 9.04。</p>
</div><h2>Shield Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Shield Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.</p>
<div class="lb-trans"><p>Shield 是一家商業階段的專業製藥公司，提供 Accrufer®/Feraccru®（鐵麥芽糖），這是一種創新且差異化的藥品，旨在滿足鐵缺乏症患者（無論是否伴有貧血）的重大未滿足需求。該公司已在美國推出 Accrufer®，並與 Viatris Inc（Viatris）簽署了獨家多年的商業協議。在美國以外，該公司已將權利授權給四家專業製藥公司。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Shield Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Shield Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Shield Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Shield Therapeutics 嗎？</h2>
</div><p>Before you consider Shield Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Shield Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Shield Therapeutics 並不在名單上。</p>
</div><p>While Shield Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Shield Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Shield Therapeutics (LON:STX) 的股價跌破了 50 日移動平均線 - 接下來會發生什麼？